Shire CFO jumps ship for Severn Trent

Departure adds to disruption for drugs group

Valeant hints at higher bid for Allergan

Pharma group plays down talks of split with Pershing Square

AbbVie hits at Treasury as Shire deal dies

González calls for comprehensive US tax reform

UK backs unlicensed medicines bill

New drugs for terminally ill would help cure cancer, says Saatchi

To stop ‘deserters’, reform tax system

New rules do nothing to deal with reasons why companies try to escape US taxes, writes Jonathan Ford

M&A deal failure at highest since 2008

A total of $573bn worth of deals have been withdrawn so far

Mylan faces pressure over US executions

Generic drugmaker’s product set to be used for lethal injections

Nigeria uses Twitter for Ebola campaign

Vibrant social media spurs community initiative to combat virus

Small-cap Week, October 18

Connect Group, Scancell, Range Resources and Vertu Motors featured

Pfizer’s Astra pursuit suffers setback

Collapse of AbbVie’s bid for Shire diminishes chances of revised offer

Week in Review, October 18

UBS, EDF, Abbvie and Shire, and luxury groups featured

Western pharmaceutical giants’ expansion plans come up against local ambitions

Fast-growing domestic producers find conditions in their favour

Investors see huge scope as better healthcare is promised in China

Opportunities in sector that is national priority and increasingly a destination for private consumption

Both medical systems and patients are crying out for care

Chances for investment exist but may not be so simple to grab

AbbVie drops proposed $54bn Shire deal

Drug groups’ tie-up is the biggest to be torpedoed by US crackdown on tax inversions

Tax changes roil inversion deals

Collapse of AbbVie-Shire does not herald the end

Roche sees sales of new cancer drugs rise

Swiss drugmaker expects single-digit sales growth

In praise of tax inversions

Tax-driven deals are pallid and shaky

AbbVie drops £32bn bombshell on Shire

Panic set in as logic of takeover faced Treasury’s tax inversions crackdown

Shire deal threat flays hedge funds

Losses as AbbVie’s £32bn deal for Dublin group is left teetering


More FT Twitter accounts